PHD2-knockdown overcomes breast cancer cell death in response to glucose starvation

NewsGuard 100/100 Score

B55α is one of the regulatory subunits of the PP2A phosphatase. This phosphatases has been associated to the control of many biological functions but the multiplicity of complexes that can be formed by the combination of different subunits renders this protein hard in its understanding. The Massimiliano Mazzone group (VIB-KU Leuven) has recently demonstrated that PP2A/B55α promotes the growth of colorectal cancer, by dephosphorylating PHD2 and modifying its enzymatic properties. PHD2 is a member of a family of enzymes crucial for the cellular response to hypoxia.

In this new work Giusy Di Conza and colleagues from the Massimiliano Mazzone lab investigated the molecular interaction between PHD2 and B55α in response to glucose starvation in the context of breast cancer cells. They showed that in a context of glucose starvation, PHD2 reduces B55α protein levels, which correlates with breast cancer cell death. In breast cancer cells, PHD2-knockdown prevents B55a degradation and overcomes cell death in response to glucose starvation. PHD2-silenced MDA-MB231 xenografts show accumulation of B55a and resistance to the glucose-competitor 2DG. Accordingly, targeting of B55α sensitizes breast cancer cells to glucose starvation.

Massimiliano Mazzone (VIB-KU Leuven): "Thanks to this work, we now better understand how some tumors can escape cancer cell death in the context of nutrient starvation. Our data show the importance of blocking PP2A simultaneously to glucose metabolism in order to induce breast cancer cell death. Overall, these findings can open new possible therapeutic perspectives in breast cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment